Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAF hybrid, on complement-mediated swine endothelial cell lysis

Transplantation

Volumn 58, Issue 7, 1994, Pages 834-840

  Miyagawa, Shuji ^a,b   Shirakura, Ryota ^a   Iwata, Kazunori ^c   Nakata, Seizoh ^a   Matsumiya, Goro ^a   Izutani, Hironori ^a   Matsuda, Hikaru ^a   Terado, Atsuko ^b   Matsumoto, Misako ^b   Nagasawa, Shigeharu ^c   Seya, Tsukasa ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b CENTER FOR ADULT DISEASES   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR; HYBRID PROTEIN; MEMBRANE COFACTOR PROTEIN;

ANIMAL CELL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DNA TRANSFECTION; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SWINE; XENOGRAFT;

ANIMAL; ANTIGENS, CD; ANTIGENS, CD55; CELLS, CULTURED; CHIMERIC PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATORS; CYTOTOXICITY, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; HYBRID CELLS; LACTATE DEHYDROGENASE; MEMBRANE GLYCOPROTEINS; SUPPORT, NON-U.S. GOV'T; SWINE; TRANSFECTION;

EID: 0028117561     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199410000-00015     Document Type: Article

References (41)

1. Auchincloss H Jr. Xenogenic transplantation: a review. Trans plantation 1988; 46: 1.
2. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825.
3. Miyagawa S, Shirakura R, Matsumiya G, et al. Prolonging dis cordant xenograft survival with anticomplement reagents, K76COOH and FUT175. Transplantation 1993; 55: 709.
4. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450.
5. Platt JL, Bach FH. The barrier to xenotransplantation. Trans plantation 1991; 52: 937.
6. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Transplantation 1992; 52: 530.
7. Loveland BE, Johnstone RW, Russel SM, Thorley BR, McKenzie IFC. CD46(MCP) confers protection from lysis by xenogenic antibodies. Transplant Proc 1993; 25: 396.
8. Cary N, Moody J, Yannoutsos N, Wallwork J, White D. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection. Transplant Proc 1993; 25: 400.
9. Zhao J, Rollins SA, Maher SE, Bothwell AFM, Sims PJ. Ampli fied gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Chem 1991; 266: 13418.
10. Iwata K, Seya T, Ariga H, Nagasawa S. Expression of hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on CHO cells; comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein. J Immunol 1994; 152: 3436.
11. Nagelkeerke JF, Barto KP, van Berkel TJC. In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cell. J Biol Chem 1983; 25: 12221.
12. Jaffe EA, Nachman NL, Becker CG, Minick CR. Culture of hu man endothelial cells derived from umbilical veins. J Clin Invest 1973; 52: 2745.
13. Lublin DM, Liszewski MK, Post TW, et al. Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP): evidence for inclusion in the multi-gene family of complement-regulatory proteins. J Exp Med 1988; 168: 181.
14. Medof ME, Lublin DM, Holers VM, et al. Cloning and charac terization of cDNA encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci USA 1987; 84: 2007.
15. Caras IW, Davitz MA, Rhee L, Weddel G, Martin DW, Nussenzweig V. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature (Lond) 1987; 325: 545.
16. Takebe Y, Seiki M, Fujisawa J, et al. The SRα promoter; an efficient and versatile mammalian cDNA expression system composed of the SV40 early promoter and the R-U5 segment of human T cell leukemia virus type 1 LTR. Mol Cell Biol 1988; 8: 466.
17. Sambrok J, Fritsch EF, Maniatis T. Molecular cloning: a labo ratory manual, 2nd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory.
18. Feigner PL, Gadek TR, Holem M, et al. Lipofection: a highly efficient, lipid mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413.
19. Seya T, Hara T, Matsumoto M, Akedo H. Quantitative analysis of membrane cofactor protein (MCP) of complement: high expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J Immunol 1990; 145: 238.
20. Hara T, Matsumoto M, Fukumori Y, et al. A monoclonal anti body against human decay-accelerating factor (DAF, CD55), D17, which lacks reactivity with semen-DAF. Immunol Lett 1993; 37: 145.
21. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983; 64: 313.
22. Lublin DM, Coyne KE. Phospholipid-anchored and transmem brane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med 1991; 174: 35.
23. Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH. Endo thelial cell antigens recognized by xenoreactive human natural antibodies. Transplantation 1990; 50: 817.
24. Tuso PJ, Cramer DV, Middleton YD, et al. Pig aortic endothelial cell antigens recognized by human IgM natural antibodies. Transplantation 1993; 56: 651.
25. Calmus Y, Ayani E, Cardoso J, et al. Target antigens of hyper acute xenogenic rejection in the rat to guinea pig and guinea pig to rat discordant combination. Transplantation 1993; 56: 778.
26. Hasan R, Van den Bogaaerde JB, Wallwork J, White DJG. Evi dence that long-term survival of concordant xenografts is achieved by inhibition of antispecies antibody production. Transplantation 1992; 54: 408.
27. Matsumiya G, Shirakura R, Miyagawa S, et al. Analysis of re jection mechanism in the rat to mouse cardiac xenotransplantation: role and characteristics of anti-endothelial cell antibodies. Transplantation 1994; 57: 1653.
28. Makrides SC, Scesney SM, Ford PJ, et al. Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement. J Biol Chem 1992; 267: 24754.
29. Fearon DT. The human C3b receptor. Springer Semin Immunopathol 1983; 6: 159.
30. Brooimans RA, van Wieringen PAM, van Es LA, Daha MR. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis. Eur J Immunol 1992; 22: 3135.
31. Miyagawa S, Shirakura R, Matsumiya G, et al. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes. Scand J Immunol 1993; 38: 37.
32. Hughes TR, Piddlsden SJ, William JD, Harrison RA, Morgan BP. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J 1992; 284: 169.
33. Van den Berg CW, Harrison RA, Morgan BP. The sheep ana logue of human CD59: purification and characterization of its complement inhibitory activity. Immunology 1993; 78: 349.
34. Asch AS, Kinoshita T, Jaffe EA, Nussenzweig V. Decay-acceler ating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 1986; 163: 221.
35. Bryant RW, Granzow CA, Siegel MI, et al. Phorbol ester in creases synthesis of decay-accelerating feactor, a phosphatidy-linositol-anchored surface protein, in human endothelial cell. J Immunol 1990; 144: 593.
36. Bryant RW, Granzow CA, Siegel MI, et al. Wheat germ aggluti nin and other selected lectins increase synthesis of decay-accelerating factor in human endothelial cells. J Immunol 1991; 147: 1856.
37. Berger M, Medof ME. Increased expression of complement decay-accelerating factor during activation of human neutrophils. J Clin Invest 1987; 79: 214.
38. Cho SW, Oglesby TJ, Hsi BL, Adams EM, Atokinson JP. Char acterization of three monoclonal antibodies to membrane cofactor protein (MCP) of the complement system and quantification of MCP by radioassay. Clin Exp Immunol 1991; 83: 257.
39. Kojima A, Iwata K, Seya T, et al. Membrane cofactor protein (MCP, CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J Immunol 1993; 151: 1519.
40. Oglesby TJ, Allen CJ, Liszewski MK, White DJG, Atkinson JP. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J Exp Med 1992; 175: 1547.
41. Miyagawa S, Shirakura R, Matsumiya G, et al. Possibility for prevention of hyperacute rejection by DAF and CD59 in xenotransplantation. Transplant Proc 1994; 26: 1235.